Telavancin — New Antimicrobial Active Against Multiresistant Gram-Positive Pathogens. Clinical and Microbiological Features in Questions and Answers
Telavancin is a first marketed representative of semisinthetic lipoglycopeptides — new generation of glycopeptide antimicrobials. Telavancin is registered for the treatment of nosocomial pneumonia and skin and soft tissue infections caused by Gram(+) microorganisms, including multiresistant strains....
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy
2015-05-01
|
| Series: | Клиническая микробиология и антимикробная химиотерапия |
| Subjects: | |
| Online Access: | https://cmac-journal.ru/publication/2015/2/cmac-2015-t17-n2-p127/cmac-2015-t17-n2-p127.pdf |
| _version_ | 1818279887809544192 |
|---|---|
| author | Dekhnich A.V. Zubareva N.A. Kozlov R.S. Popov D.A. Romanov A.V. Rudnov V.A. |
| author_facet | Dekhnich A.V. Zubareva N.A. Kozlov R.S. Popov D.A. Romanov A.V. Rudnov V.A. |
| author_sort | Dekhnich A.V. |
| collection | DOAJ |
| description | Telavancin is a first marketed representative of semisinthetic lipoglycopeptides — new generation of glycopeptide antimicrobials. Telavancin is registered for the treatment of nosocomial pneumonia and skin and soft tissue infections caused by Gram(+) microorganisms, including multiresistant strains. Another perspective area of telavancin use — bloodstream infections, such as bacteremia and endocarditis. Telavancin is in vitro active against broad range of Gram(+) aerobic and anaerobic bacteria, including strains resistant to other antimicrobials: MRSA, MRSE, VISA, daptomycin non-susceptible strains of S. aureus, penicillin-resistant S. pneumoniae, ampicillin-resistant enterococci and enterococci with VanB phenotype of resistance to vancomycin. Talavancin is rapidly bactericidal due to its dual mechanism of action; it is active against intracellular bacterial cells and biofilmforming cells. Article reviews data of current in vitro and in vivo studies of telavancin, as well as clinical trials results. |
| first_indexed | 2024-12-12T23:40:29Z |
| format | Article |
| id | doaj.art-85148433f8254b5ca9b08898359e5053 |
| institution | Directory Open Access Journal |
| issn | 1684-4386 2686-9586 |
| language | Russian |
| last_indexed | 2024-12-12T23:40:29Z |
| publishDate | 2015-05-01 |
| publisher | Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy |
| record_format | Article |
| series | Клиническая микробиология и антимикробная химиотерапия |
| spelling | doaj.art-85148433f8254b5ca9b08898359e50532022-12-22T00:07:13ZrusInterregional Association for Clinical Microbiology and Antimicrobial ChemotherapyКлиническая микробиология и антимикробная химиотерапия1684-43862686-95862015-05-01172127145cmac-2015-t17-n2-p127Telavancin — New Antimicrobial Active Against Multiresistant Gram-Positive Pathogens. Clinical and Microbiological Features in Questions and AnswersDekhnich A.V.0Zubareva N.A.1Kozlov R.S.2Popov D.A.3Romanov A.V.4Rudnov V.A.5Institute of Antimicrobial Chemotherapy, Smolensk, RussiaPerm State Medical University, Perm, RussiaInstitute of Antimicrobial Chemotherapy, Smolensk, RussiaScientific Centre of Cardiac Surgery named after A.N. Bakulev, Moscow, RussiaInstitute of Antimicrobial Chemotherapy, Smolensk, RussiaUral State Medical University, Perm, RussiaTelavancin is a first marketed representative of semisinthetic lipoglycopeptides — new generation of glycopeptide antimicrobials. Telavancin is registered for the treatment of nosocomial pneumonia and skin and soft tissue infections caused by Gram(+) microorganisms, including multiresistant strains. Another perspective area of telavancin use — bloodstream infections, such as bacteremia and endocarditis. Telavancin is in vitro active against broad range of Gram(+) aerobic and anaerobic bacteria, including strains resistant to other antimicrobials: MRSA, MRSE, VISA, daptomycin non-susceptible strains of S. aureus, penicillin-resistant S. pneumoniae, ampicillin-resistant enterococci and enterococci with VanB phenotype of resistance to vancomycin. Talavancin is rapidly bactericidal due to its dual mechanism of action; it is active against intracellular bacterial cells and biofilmforming cells. Article reviews data of current in vitro and in vivo studies of telavancin, as well as clinical trials results.https://cmac-journal.ru/publication/2015/2/cmac-2015-t17-n2-p127/cmac-2015-t17-n2-p127.pdftelavancinglycopeptidesmrsaskin and soft tissue infectionsnosocomial pneumoniabloodstream infections |
| spellingShingle | Dekhnich A.V. Zubareva N.A. Kozlov R.S. Popov D.A. Romanov A.V. Rudnov V.A. Telavancin — New Antimicrobial Active Against Multiresistant Gram-Positive Pathogens. Clinical and Microbiological Features in Questions and Answers Клиническая микробиология и антимикробная химиотерапия telavancin glycopeptides mrsa skin and soft tissue infections nosocomial pneumonia bloodstream infections |
| title | Telavancin — New Antimicrobial Active Against Multiresistant Gram-Positive Pathogens. Clinical and Microbiological Features in Questions and Answers |
| title_full | Telavancin — New Antimicrobial Active Against Multiresistant Gram-Positive Pathogens. Clinical and Microbiological Features in Questions and Answers |
| title_fullStr | Telavancin — New Antimicrobial Active Against Multiresistant Gram-Positive Pathogens. Clinical and Microbiological Features in Questions and Answers |
| title_full_unstemmed | Telavancin — New Antimicrobial Active Against Multiresistant Gram-Positive Pathogens. Clinical and Microbiological Features in Questions and Answers |
| title_short | Telavancin — New Antimicrobial Active Against Multiresistant Gram-Positive Pathogens. Clinical and Microbiological Features in Questions and Answers |
| title_sort | telavancin new antimicrobial active against multiresistant gram positive pathogens clinical and microbiological features in questions and answers |
| topic | telavancin glycopeptides mrsa skin and soft tissue infections nosocomial pneumonia bloodstream infections |
| url | https://cmac-journal.ru/publication/2015/2/cmac-2015-t17-n2-p127/cmac-2015-t17-n2-p127.pdf |
| work_keys_str_mv | AT dekhnichav telavancinnewantimicrobialactiveagainstmultiresistantgrampositivepathogensclinicalandmicrobiologicalfeaturesinquestionsandanswers AT zubarevana telavancinnewantimicrobialactiveagainstmultiresistantgrampositivepathogensclinicalandmicrobiologicalfeaturesinquestionsandanswers AT kozlovrs telavancinnewantimicrobialactiveagainstmultiresistantgrampositivepathogensclinicalandmicrobiologicalfeaturesinquestionsandanswers AT popovda telavancinnewantimicrobialactiveagainstmultiresistantgrampositivepathogensclinicalandmicrobiologicalfeaturesinquestionsandanswers AT romanovav telavancinnewantimicrobialactiveagainstmultiresistantgrampositivepathogensclinicalandmicrobiologicalfeaturesinquestionsandanswers AT rudnovva telavancinnewantimicrobialactiveagainstmultiresistantgrampositivepathogensclinicalandmicrobiologicalfeaturesinquestionsandanswers |